Glaxo could soon tap the second half of a $6B respiratory market

March 20, 2015 5:48 PM

4 0

Glaxo could soon tap the second half of a $6B respiratory market

An FDA advisory committee voted to recommend approval of GSK’s next-generation respiratory drug, something that would open the drug up to another half of a $6 billion market in the United States.

GlaxoSmithKline (NYSE: GSK) already holds approval from the U.S. Food and Drug Administration to market Breo Ellipta as a treatment for Chronic Obstructive Pulmonary Disease (COPD), about 40 percent of the $6 billion market for this type of respiratory medicine.

Also read: Texas Gives Herman 5 Years, Minimum of $25 Million

Read more

To category page

Loading...